Paradigm shift in the treatment options of hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Paradigm shift in the treatment options of hepatocellular carcinoma

Published:2021-09-17 Issue: Volume: Page:
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Su Tung‐Hung¹²^ORCID,Hsu Shih‐Jer¹²³^ORCID,Kao Jia‐Horng¹²⁴⁵^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan

2. Hepatitis Research CenterNational Taiwan University Hospital Taipei Taiwan

3. Division of Gastroenterology and Hepatology Department of Internal Medicine National Taiwan University Hospital Yun‐Lin Branch Yunlin Taiwan

4. Graduate Institute of Clinical MedicineNational Taiwan University College of Medicine Taipei Taiwan

5. Department of Medical Research National Taiwan University Hospital Taipei Taiwan

Funder

Ministry of Science and Technology, Taiwan

National Taiwan University Hospital

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.15052

Reference145 articles.

1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

4. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

5. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Ramucirumab as a combinational cancer therapeutic with 5-Aza- citidine in human Hepatoma (HuH-7) cell line;Journal of King Saud University - Science;2024-10

2. Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy;Journal of the Formosan Medical Association;2024-08

3. Prognostic Role of Lymphocyte-to-Monocyte Ratio (LMR) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Undergoing Chemoembolizations (DEM-TACE or cTACE) of the Liver: Exploring the Link between Tumor Microenvironment and Interventional Radiology;Diseases;2024-06-27

4. Carrier-Free Self-Assembled Nanomedicines for Promoting Apoptosis and Inhibiting Proliferation in Hepatocellular Carcinoma;ACS Biomaterials Science & Engineering;2024-06-06

5. A Multicenter International Retrospective Investigation Assessing the Prognostic Role of Inflammation-Based Scores (Neutrophil-to-Lymphocyte, Lymphocyte-to-Monocyte, and Platelet-to-Lymphocyte Ratios) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Undergoing Chemoembolizations of the Liver;Cancers;2024-04-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3